Skip to main content
Erschienen in: Brain Tumor Pathology 4/2019

19.07.2019 | Original Article

Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II–III gliomas to establish genetic predictors of poor prognosis

verfasst von: Kiyonori Kuwahara, Shigeo Ohba, Shunsuke Nakae, Natsuki Hattori, Eriel Sandika Pareira, Seiji Yamada, Hikaru Sasaki, Masato Abe, Mitsuhiro Hasegawa, Yuichi Hirose

Erschienen in: Brain Tumor Pathology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

The genetic features of isocitrate dehydrogenase-wild-type (IDH-wt) lower-grade gliomas (LGGs; World Health Organization grades II and III) are not well defined. This study analyzed the genetic and other features of IDH-wt LGGs to develop a subclassification that can be used to predict their prognosis. Clinical, histopathological, and genetic features of 35 cases of diffuse IDH-wt astrocytoma and IDH-wt anaplastic astrocytoma were analyzed. The following genetic factors were examined: mutations of B-rapidly accelerated fibrosarcoma, telomerase reverse transcriptase promoter (TERTp), histone 3 family 3A, and alpha-thalassemia/mental retardation syndrome, X-linked; and copy number aberrations. In the univariate analysis, the following factors were associated with poor overall survival (OS): the histopathological diagnosis, TERTp mutation, the gain of chromosome 7 (+ 7), and the loss of chromosome 10q (− 10q). In the multivariate analysis, + 7, − 10q, and TERTp mutation were independent prognostic factors associated with poor OS. The median OS was significantly worse for patients who harbored at least one of these factors than for those without any of them (18.5 vs. 54.5 months, P = 0.002). The subclassification of IDH-wt LGGs according to the genetic factors + 7, − 10q, and TERTp mutation is potentially useful for predicting the prognosis.
Literatur
1.
Zurück zum Zitat Louis DN, Ohgaki H, Wiestler OD et al (2016) WHO classification of tumours of the central nervous system, 4th edn. IARC, Lyon Louis DN, Ohgaki H, Wiestler OD et al (2016) WHO classification of tumours of the central nervous system, 4th edn. IARC, Lyon
2.
Zurück zum Zitat Wijnenga MMJ, Dubbink HJ, French PJ et al (2017) Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol 134:957–959CrossRef Wijnenga MMJ, Dubbink HJ, French PJ et al (2017) Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol 134:957–959CrossRef
3.
Zurück zum Zitat Aibaidula A, Chan AKY, Shi Z et al (2017) Adult IDH wild-type lower grade gliomas should be further stratified. Neuro Oncol 19(10):1327–1337CrossRef Aibaidula A, Chan AKY, Shi Z et al (2017) Adult IDH wild-type lower grade gliomas should be further stratified. Neuro Oncol 19(10):1327–1337CrossRef
4.
Zurück zum Zitat Weller M, Weber RG, Willscher E et al (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679–693CrossRef Weller M, Weber RG, Willscher E et al (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679–693CrossRef
5.
Zurück zum Zitat Stichel D, Ebrahimi A, Reuss D et al (2018) Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol 136(5):793–803CrossRef Stichel D, Ebrahimi A, Reuss D et al (2018) Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol 136(5):793–803CrossRef
6.
Zurück zum Zitat Brat DJ, Aldape K, Colman H et al (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol 136(5):805–810CrossRef Brat DJ, Aldape K, Colman H et al (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol 136(5):805–810CrossRef
7.
Zurück zum Zitat Aoki K, Nakamura H, Suzuki H et al (2018) Prognostic relevance of genetic alterations in diffuse lower-grade glioma. Neuro Oncol 20(1):66–77CrossRef Aoki K, Nakamura H, Suzuki H et al (2018) Prognostic relevance of genetic alterations in diffuse lower-grade glioma. Neuro Oncol 20(1):66–77CrossRef
8.
Zurück zum Zitat van den Bent MJ, Weller M, Wen PY et al (2017) A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro Oncol 19(5):614–624CrossRef van den Bent MJ, Weller M, Wen PY et al (2017) A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro Oncol 19(5):614–624CrossRef
9.
Zurück zum Zitat Hirose Y, Sasaki H, Miwa T et al (2011) Whole genome analysis from microdissected tissue revealed adult supratentorial grade II–III gliomas are divided into clinically relevant subgroups by genetic plofiles. Neurosurgery 69(2):376–390CrossRef Hirose Y, Sasaki H, Miwa T et al (2011) Whole genome analysis from microdissected tissue revealed adult supratentorial grade II–III gliomas are divided into clinically relevant subgroups by genetic plofiles. Neurosurgery 69(2):376–390CrossRef
10.
Zurück zum Zitat Hattori N, Hirose Y, Sasaki H et al (2016) World Health Organization grade II–III astrocytomas consist of genetically distinct tumor lineages. Cancer Sci 107(8):1159–1164CrossRef Hattori N, Hirose Y, Sasaki H et al (2016) World Health Organization grade II–III astrocytomas consist of genetically distinct tumor lineages. Cancer Sci 107(8):1159–1164CrossRef
11.
Zurück zum Zitat Arslantas A, Artan S, Oner U et al (2007) Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas. Pathol Oncol Res 13(1):39–46CrossRef Arslantas A, Artan S, Oner U et al (2007) Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas. Pathol Oncol Res 13(1):39–46CrossRef
12.
Zurück zum Zitat Koelsche C, Sahm F, Capper D et al (2013) Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 126(6):907–915CrossRef Koelsche C, Sahm F, Capper D et al (2013) Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 126(6):907–915CrossRef
13.
Zurück zum Zitat Liu XY, Gerges N, Korshunov A et al (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124(5):615–625CrossRef Liu XY, Gerges N, Korshunov A et al (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124(5):615–625CrossRef
14.
Zurück zum Zitat Schindler G, Capper D, Meyer J et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397–405CrossRef Schindler G, Capper D, Meyer J et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397–405CrossRef
15.
Zurück zum Zitat Dahiya S, Emnett RJ, Haydon DH et al (2014) BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro Oncol 16(2):318–319CrossRef Dahiya S, Emnett RJ, Haydon DH et al (2014) BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro Oncol 16(2):318–319CrossRef
16.
Zurück zum Zitat Pekmezci M, Rice T, Molinaro AM et al (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133(6):1001–1016CrossRef Pekmezci M, Rice T, Molinaro AM et al (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133(6):1001–1016CrossRef
17.
Zurück zum Zitat Bloch O, Han SJ, Cha S et al (2012) Impact of extent of resection for recurrent glioblastoma on overall survival. J Neurosurg 117:1032–1038CrossRef Bloch O, Han SJ, Cha S et al (2012) Impact of extent of resection for recurrent glioblastoma on overall survival. J Neurosurg 117:1032–1038CrossRef
18.
Zurück zum Zitat Wisoff JH, Boyett JM, Berger MS et al (1998) Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children’s Cancer Group trial no. CCG-945. J Neurosurg 89(1):52–59CrossRef Wisoff JH, Boyett JM, Berger MS et al (1998) Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children’s Cancer Group trial no. CCG-945. J Neurosurg 89(1):52–59CrossRef
19.
Zurück zum Zitat Almenawer SA, Badhiwala JH, Alhazzani W et al (2015) Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. Neuro Oncol 17(6):868–881CrossRef Almenawer SA, Badhiwala JH, Alhazzani W et al (2015) Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. Neuro Oncol 17(6):868–881CrossRef
20.
Zurück zum Zitat Nakagawa Y, Sasaki H, Ohara K et al (2017) Clinical and molecular prognostic factors for long-term survival of patients with glioblastomas in single-institutional consecutive cohort. World Neurosurg 106:165–173CrossRef Nakagawa Y, Sasaki H, Ohara K et al (2017) Clinical and molecular prognostic factors for long-term survival of patients with glioblastomas in single-institutional consecutive cohort. World Neurosurg 106:165–173CrossRef
21.
Zurück zum Zitat Liu X, Bishop J, Shan Y et al (2013) Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 20(4):603–610CrossRef Liu X, Bishop J, Shan Y et al (2013) Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 20(4):603–610CrossRef
22.
Zurück zum Zitat Huang T, Zhuge J, Zhang W (2013) Sensitive detection of BRAF V600E mutation by amplification refractory mutation system (ARMS)-PCR. Biomark Res 1:3CrossRef Huang T, Zhuge J, Zhang W (2013) Sensitive detection of BRAF V600E mutation by amplification refractory mutation system (ARMS)-PCR. Biomark Res 1:3CrossRef
23.
Zurück zum Zitat Zhang R, Shi Z, Chen H et al (2015) Biomarker-based prognostic stratification of young adult glioblastoma. Oncotarget 7(4):5030–5041PubMedCentral Zhang R, Shi Z, Chen H et al (2015) Biomarker-based prognostic stratification of young adult glioblastoma. Oncotarget 7(4):5030–5041PubMedCentral
24.
Zurück zum Zitat Gielen GH, Gessi M, Hammes J et al (2013) H3F3A K27M mutation in pediatric CNS tumors a marker for diffuse high-grade astrocytomas. Am J Clin Pathol 139(3):345–349CrossRef Gielen GH, Gessi M, Hammes J et al (2013) H3F3A K27M mutation in pediatric CNS tumors a marker for diffuse high-grade astrocytomas. Am J Clin Pathol 139(3):345–349CrossRef
25.
Zurück zum Zitat Olar A, Wani KM, Alfaro-Munoz KD et al (2015) IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol 129(4):585–596CrossRef Olar A, Wani KM, Alfaro-Munoz KD et al (2015) IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol 129(4):585–596CrossRef
26.
Zurück zum Zitat Hewer E, Vajtai I, Dettmer MS et al (2016) Combined ATRX/IDH immunohistochemistry predicts genotype of oligoastrocytomas. Histopathol 68:272–278CrossRef Hewer E, Vajtai I, Dettmer MS et al (2016) Combined ATRX/IDH immunohistochemistry predicts genotype of oligoastrocytomas. Histopathol 68:272–278CrossRef
27.
Zurück zum Zitat Wiestler B, Capper D, Holland-Letz T et al (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451CrossRef Wiestler B, Capper D, Holland-Letz T et al (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451CrossRef
28.
Zurück zum Zitat Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl 48(3):452–458CrossRef Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl 48(3):452–458CrossRef
29.
Zurück zum Zitat Pallud J, Fontaine D, Duffau H et al (2010) Natural history of incidental World Health Organization grade II gliomas. Ann Neurol 68(5):727–733CrossRef Pallud J, Fontaine D, Duffau H et al (2010) Natural history of incidental World Health Organization grade II gliomas. Ann Neurol 68(5):727–733CrossRef
30.
Zurück zum Zitat Reinhardt A, Stichel D, Schrimpf D et al (2018) Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol 136(2):273–291CrossRef Reinhardt A, Stichel D, Schrimpf D et al (2018) Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol 136(2):273–291CrossRef
Metadaten
Titel
Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II–III gliomas to establish genetic predictors of poor prognosis
verfasst von
Kiyonori Kuwahara
Shigeo Ohba
Shunsuke Nakae
Natsuki Hattori
Eriel Sandika Pareira
Seiji Yamada
Hikaru Sasaki
Masato Abe
Mitsuhiro Hasegawa
Yuichi Hirose
Publikationsdatum
19.07.2019
Verlag
Springer Singapore
Erschienen in
Brain Tumor Pathology / Ausgabe 4/2019
Print ISSN: 1433-7398
Elektronische ISSN: 1861-387X
DOI
https://doi.org/10.1007/s10014-019-00348-9

Weitere Artikel der Ausgabe 4/2019

Brain Tumor Pathology 4/2019 Zur Ausgabe

Acknowledgment

Reviewers in 2019

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.